A faster route to eliminating parasitic infection endemic to Africa

A recent clinical trial finds the anti-parasitic drug moxidectin -- currently approved to treat river blindness, another tropical disease caused by parasitic worms -- is also more effective for lymphatic filariasis than the current gold standard, ivermectin.

A recent clinical trial finds the anti-parasitic drug moxidectin -- currently approved to treat river blindness, another tropical disease caused by parasitic worms -- is also more effective for lymphatic filariasis than the current gold standard, ivermectin.

Read more https://www.sciencedaily.com/releases/2025/05/250507141222.htm